| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-03-31 |
|---|---|---|---|---|
| Collaboration revenue | 1,299 | 1,591* | 1,741 | 1,629 |
| Research and development | 24,703 | 25,368* | 25,838 | 29,136 |
| General and administrative | 9,596 | 9,905* | 10,638 | 13,773 |
| Impairment loss | NaN | 0* | NaN | NaN |
| Total operating expenses | 34,299 | 35,272* | 36,476 | 42,909 |
| Loss from operations | -33,000 | -33,681* | -34,735 | -41,280 |
| Interest income | 1,867 | 2,186* | 2,575 | 3,336 |
| Change in fair value of stock price appreciation milestones | 80 | 41* | 90 | -280 |
| Other income | 0 | 29* | 0 | 43 |
| Total other income | 1,787 | 2,173* | 2,485 | 3,659 |
| Net loss | -31,213 | -31,508* | -32,250 | -37,621 |
| Unrealized loss on available-for-sale securities, net | -193 | -173* | 91 | -77 |
| Comprehensive loss | -31,406 | -31,681 | -32,159 | -37,698 |
| Basic EPS | -0.26 | -0.266 | -0.27 | -0.32 |
| Diluted EPS | -0.26 | -0.266 | -0.27 | -0.32 |
| Basic Average Shares | 120,030,638 | 118,995,689 | 118,998,693 | 118,375,540 |
| Diluted Average Shares | 120,030,638 | 118,995,689 | 118,998,693 | 118,375,540 |
FATE THERAPEUTICS INC (FATE)
FATE THERAPEUTICS INC (FATE)